Altamira Therapeutics Ltd.

Equities

CYTO

BMG0360L1349

Biotechnology & Medical Research

End-of-day quote Nasdaq 07:00:00 2024-03-25 pm EDT 5-day change 1st Jan Change
2.42 USD +2.98% Intraday chart for Altamira Therapeutics Ltd. +43.20% -30.46%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Decline Late Afternoon MT
Top Midday Gainers MT
Sector Update: Health Care Stocks Softer in Afternoon Trading MT
Altamira, Univercells Partner to Test mRNA Vaccine Delivery; Shares Surge MT
Altamira Therapeutics Ltd. Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines CI
Altamira Therapeutics? Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal CI
Altamira Files Second Provisional Patent Application in Cancer Treatment; Shares Rise MT
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment CI
Altamira Therapeutics Back in Compliance with Nasdaq Minimum Bid Price Rules MT
Transcript : Altamira Therapeutics Ltd. - Special Call
Altamira Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders Equity Requirement MT
An unknown private equity investor acquired 51% stake in Altamira Medica AG from Altamira Therapeutics Ltd.. CI
Sector Update: Health Care Stocks Slipping Late Afternoon MT
Top Midday Gainers MT
Altamira Therapeutics to Sell 51% of Bentrio Maker for $2.3 Million MT
An unknown private equity investor entered into a binding agreement to acquire 51% stake in Altamira Medica AG from Altamira Therapeutics Ltd. for CHF 2.04 million. CI
Altamira Therapeutics Ltd. Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis CI
Transcript : Altamira Therapeutics Ltd., H1 2023 Earnings Call, Sep 12, 2023
Altamira Therapeutics Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Altamira Therapeutics Collaborating With Pharma Nordic to Market, Distribute Bentrio Nasal Spray in Scandinavia MT
Altamira Therapeutics, Heqet Therapeutics Enter Into Collaboration for OligoPhore Platform MT
Altamira Therapeutics Receives Non-Compliance Notice From Nasdaq MT
Altamira Therapeutics Ltd. Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular Syndrome CI
Altamira Therapeutics Ltd. announced that it has received CHF 2.5 million in funding from FiveT Investment Management Ltd. CI
Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis CI
Chart Altamira Therapeutics Ltd.
More charts
Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell growth and proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.
More about the company
  1. Stock
  2. Equities
  3. Stock Altamira Therapeutics Ltd. - Nasdaq
  4. News Altamira Therapeutics Ltd.
  5. Sector Update: Health Care Stocks Drift Away from Midday Highs